Drug–target residence time: critical information for lead optimization

Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug–target binding are flawed, since this approach ignores the fluctuatio...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in chemical biology 2010-08, Vol.14 (4), p.467-474
Main Authors: Lu, Hao, Tonge, Peter J
Format: Article
Language:English
Subjects:
Drug Delivery Systems - methods
Drug Design
Humans
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - metabolism
Pharmacokinetics
Technology, Pharmaceutical
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug–target binding are flawed, since this approach ignores the fluctuations in drug concentration that occur in vivo. Instead the lifetime of the drug–target complex must also be considered, since drugs only act when they are bound to their targets. Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug–target residence time must be incorporated into the drug discovery process.
ISSN:1367-5931
1879-0402
DOI:10.1016/j.cbpa.2010.06.176